Skip to main content

Advertisement

Table 4 Proportion and Rates of Adverse Events that are Probably or Possibly Related to Adalimumab Observed in More Than 1% of the Patients

From: Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): Results from the CanACT study

Adverse events observed in
> 1% of the patients
(probably or possibly related to adalimumab)
No. of Events No. of Patients Patients (%) Events per 100 patient-years
Injection site reaction NOSa 145 87 9.9 39.0
Headache 63 46 5.2 16.9
Injection site erythema 55 31 3.5 14.8
Nausea 38 26 3 10.2
Rash NOS 26 25 2.8 7.0
Diarrhea NOS 27 22 2.5 7.3
Fatigue 21 16 1.8 5.6
Upper respiratory tract infection NOS 17 16 1.8 4.6
Injection site pruritus 23 13 1.5 6.2
Dizziness 12 12 1.4 3.2
Pruritus 14 12 1.4 3.8
Rheumatoid arthritis 14 12 1.4 3.8
Nasopharyngitis 13 11 1.3 3.5
Adverse drug reaction 11 10 1.1 3.0
Injection site rash 11 10 1.1 3.0
Urinary tract infection NOS 10 9 1 2.7
  1. aDefined as localized injection-site bruising, burning, dermatitis, erythema, induration, inflammation, irritation, mass, edema, pain, pruritus, rash, stinging, swelling, and warmth.
  2. NOS: not otherwise specified.